CliffBio
small molecule

ONZETRA XSAIL

SUMATRIPTAN SUCCINATE

Loss of exclusivityOctober 2034latest FDA-listed patent expiry
CompanyCurrax Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameONZETRA XSAIL
Active ingredientSUMATRIPTAN SUCCINATE
StrengthEQ 11MG BASE
Dosage formPOWDER
RouteNASAL
ModalitySmall molecule
FDA approvalJanuary 2016
Marketing statusRX

Listed patents

PatentExpiresType
10076614October 2034product
10478574November 2033use U-2404
8978647December 2030product
9649456October 2030product
8899229August 2030product
8550073October 2029product
10076615July 2029use U-2404
10722667December 2028product
8875704April 2028product
10398859December 2027product
10124132March 2027product
11571531February 2026use U-1809

More from Currax Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ONZETRA XSAIL patent cliff — loss of exclusivity October 2034 | CliffBio